Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology.

ABSTRACT: Endometrial cancer (EC) can easily be cured when diagnosed at an early stage. However, advanced and metastatic EC is a common disease, affecting more than 15,000 patients per year in the United Sates. Only limited treatment options were available until recently, with a taxane-platinum combination as the gold standard in first-line setting and no efficient second-line chemotherapy or hormone therapy. EC can be split into four molecular subtypes, including hypermutated cases with POLE mutations and 25-30% harboring a microsatellite instability (MSI) phenotype with mismatch repair deficiency (dMMR). These tumors display a high load of frameshift mutations, leading to increased expression of neoantigens that can be targeted by the immune system, including (but not limited) to T-cell response.

SUBMITTER: Rousset-Rouviere S 

PROVIDER: S-EPMC8228955 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature